Last updated: 11 February 2022 at 1:55pm EST

Dr. Charles J. Fisher Jr., M.D. Net Worth



Dr. Charles J. Fisher Jr., M.D. biography

Dr. Charles J. Fisher Jr., M.D. is the CEO, Director & Member of Extracorporeal Therapy Advisory Board at Aethlon Medical Inc.

What is the salary of Dr D?

As the CEO e Director & Member of Extracorporeal Therapy Advisory Board of Aethlon Medical Inc, the total compensation of Dr D at Aethlon Medical Inc is $509,137. There are 1 executives at Aethlon Medical Inc getting paid more, with Steven P. Larosa M.D. having the highest compensation of $513,800.



How old is Dr D?

Dr D is 74, he's been the CEO e Director & Member of Extracorporeal Therapy Advisory Board of Aethlon Medical Inc since . There are 2 older and 6 younger executives at Aethlon Medical Inc. The oldest executive at Aethlon Medical Inc is Edward Broenniman, 84, who is the Chairman of the Board.

What's Dr D's mailing address?

Charles's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 203, , SAN DIEGO, CA, 92121.

Insiders trading at Aethlon Medical Inc

Over the last 11 years, insiders at Aethlon Medical Inc have traded over $56,658 worth of Aethlon Medical Inc stock. The most active insiders traders include James A Joyce, Angela Rossetti e Chetan Shah. On average, Aethlon Medical Inc executives and independent directors trade stock every 56 days with the average trade being worth of $4,427. The most recent stock trade was executed by Chetan Shah on 17 December 2020, trading 26,852 units of AEMD stock currently worth $56,658.



What does Aethlon Medical Inc do?

the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.



Aethlon Medical Inc executives and stock owners

Aethlon Medical Inc executives and other stock owners filed with the SEC include: